• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Womack Kelvin K.

    4/27/23 4:35:24 PM ET
    $CSII
    Medical/Dental Instruments
    Health Care
    Get the next $CSII alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Womack Kelvin K.

    (Last) (First) (Middle)
    1225 OLD HIGHWAY 8 NW

    (Street)
    ST. PAUL MN 55112

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Cardiovascular Systems Inc [ CSII ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/27/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 04/27/2023 D 16,734 (1) (1) Common Stock 16,734 $0 0 D
    Explanation of Responses:
    1. Pursuant to the Agreement and Plan of Merger by and among Cardiovascular Systems, Inc., a Delaware corporation, Abbott Laboratories, an Illinois corporation, and Cobra Acquisition Co., a Delaware corporation (the "Merger Agreement"), each unvested restricted stock unit became fully vested immediately prior to the effective time of the merger. Restricted stock units were then cancelled as of the effective time of the merger in exchange for the right to receive a cash payment equal to $20.00 multiplied by the number of restricted stock units, without interest and less any required withholding of taxes.
    /s/ Andrew Nick as Attorney-in-Fact for Kelvin K. Womack pursuant to Power of Attorney previously filed. 04/27/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CSII alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CSII

    DatePrice TargetRatingAnalyst
    12/21/2022$15.00Equal Weight
    Barclays
    12/14/2022$25.00Buy
    Lake Street
    3/2/2022$22.00Underperform
    BofA Securities
    2/4/2022$25.00 → $20.00Outperform
    SVB Leerink
    11/17/2021Buy → Hold
    Needham
    11/10/2021Buy → Neutral
    Guggenheim
    11/10/2021$45.00 → $40.00Outperform
    SVB Leerink
    9/23/2021$50.00 → $49.00Buy
    Needham
    More analyst ratings

    $CSII
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cytek Biosciences Set to Join S&P SmallCap 600

      NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector May 1, 2023 S&P SmallCap 600 Addition Cytek Biosciences CTKB Health Care S&P SmallCap 600 Deletion Cardiovascular Systems CSII Health C

      4/25/23 5:54:00 PM ET
      $ABT
      $CSII
      $CTKB
      $SPGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Laboratory Analytical Instruments
    • Cardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical Trial

      Largest randomized coronary atherectomy trial ever conducted Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company completed the enrollment of its 2,000 patient ECLIPSE coronary trial. ECLIPSE is a prospective, multi-center, randomized clinical trial of approximately 2,000 subjects with severely calcified coronary lesions in the United States. Half of the participants received orbital atherectomy prior to drug-eluting stent implantation, while the other half received conventional angioplasty, including speci

      4/3/23 4:05:00 PM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results

      Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin

      2/8/23 6:12:00 PM ET
      $ABT
      $CSII
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments

    $CSII
    SEC Filings

    See more
    • SEC Form 15-12G filed by Cardiovascular Systems Inc.

      15-12G - Cardiovascular Systems Inc (0001180145) (Filer)

      5/8/23 6:00:37 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Cardiovascular Systems Inc.

      S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)

      5/1/23 6:03:42 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Cardiovascular Systems Inc.

      S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)

      5/1/23 6:05:14 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care

    $CSII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cardiovascular Systems Inc. (Amendment)

      SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)

      2/13/24 3:24:48 PM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Cardiovascular Systems Inc. (Amendment)

      SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)

      2/14/23 9:00:06 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Cardiovascular Systems Inc. (Amendment)

      SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)

      2/13/23 1:26:27 PM ET
      $CSII
      Medical/Dental Instruments
      Health Care

    $CSII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Womack Kelvin K.

      4 - Cardiovascular Systems Inc (0001180145) (Issuer)

      4/27/23 4:35:24 PM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Paulsen Erik

      4 - Cardiovascular Systems Inc (0001180145) (Issuer)

      4/27/23 4:38:00 PM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Points Jeffrey S.

      4 - Cardiovascular Systems Inc (0001180145) (Issuer)

      4/27/23 4:37:02 PM ET
      $CSII
      Medical/Dental Instruments
      Health Care

    $CSII
    Financials

    Live finance-specific insights

    See more
    • Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results

      Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin

      2/8/23 6:12:00 PM ET
      $ABT
      $CSII
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Cardiovascular Systems, Inc. to Host Earnings Conference Call on February 9, 2023

      Cardiovascular Systems, Inc. (NASDAQ:CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results. Click here to access the live webcast. A replay will be available later the same day. Click here to register for the conference call. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic pla

      1/19/23 7:00:00 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results

      Conference Call Scheduled for Today, November 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET)  Revenues of $59.7 million increased 2.2% compared to first quarter last year Management reiterates fiscal 23 revenue guidance of $255 million to $265 million, representing 8% to 12% growth Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its first quarter, ended September 30, 2022. Executive Commentary – Scott Ward, Chairman, President and CEO "We are pleased with the state of our business and our perfor

      11/3/22 7:00:00 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care

    $CSII
    Leadership Updates

    Live Leadership Updates

    See more
    • Big Sky Biomedical Appoints Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director

      MINNEAPOLIS, March 7, 2022 /PRNewswire-PRWeb/ -- Big Sky Biomedical, a leading-edge medical device and health technology incubator, announced today that it has appointed Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director. "Big Sky Biomedical was founded to enhance early-stage innovation and development in some of the fastest growing segments of healthcare, including neurovascular, structural heart, and regenerative medicine," said Dr. Egeland. "I'm extremely excited to apply my scientific, medical, and commercial experience to our portfolio companies in a much broader and deeper capacity. Alongside our exceptional teams of engineers, scientists, operators, and physician partners, I loo

      3/7/22 12:00:00 PM ET
      $CSII
      $MDT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Cardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D., as Chief Medical Officer

      Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary vascular disease, today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer. "CSI is developing an exciting product pipeline that targets some of the fastest growing segments of interventional cardiology," said Scott Ward, Chairman, President and Chief Executive Officer. "Jeff brings contemporary interventional cardiology practice and extensive clinical research experience to CSI as we seek to expand our product offering beyond orbital atherectomy. We believe Jeff brings valuable per

      3/4/22 7:00:00 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

      CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

      2/9/21 4:01:00 PM ET
      $CSII
      $MEI
      $CNMD
      Medical/Dental Instruments
      Health Care
      Electrical Products
      Technology

    $CSII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on Cardiovascular Systems with a new price target

      Barclays initiated coverage of Cardiovascular Systems with a rating of Equal Weight and set a new price target of $15.00

      12/21/22 7:41:39 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Cardiovascular Systems with a new price target

      Lake Street initiated coverage of Cardiovascular Systems with a rating of Buy and set a new price target of $25.00

      12/14/22 9:03:31 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • BofA Securities resumed coverage on Cardiovascular Systems with a new price target

      BofA Securities resumed coverage of Cardiovascular Systems with a rating of Underperform and set a new price target of $22.00

      3/2/22 7:23:56 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care